Biomarkers such as BRAF V600E mutations, NTRK and RET fusions, high tumor mutational burden (TMB-H), and dMMR/MSI-H have not only expanded the armamentarium of targeted and immunotherapeutic agents but have also facilitated more personalized care with the potential for improved survival and quality of life. This evidence concerns the gene RET and neoplasm.